Spero Therapeutics Business Summary

Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company specializing in the development of novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company’s business model is primarily driven by strategic licensing and collaboration agreements, generating revenue through upfront payments, milestone-based fees, and future royalties, supplemented by government research grants. Its lead asset, tebipenem HBr, is an investigational oral carbapenem for complicated urinary tract infections (cUTI) being advanced through a high-value partnership with GSK, which handles global commercialization outside of select Asian territories. Spero competes directly with other anti-infective specialists such as Melinta Therapeutics, Iterum Therapeutics, and Nabriva Therapeutics, positioning itself as a late-stage developer that mitigates commercial risk by leveraging the infrastructure of large-cap pharmaceutical partners. Spero was founded by Dr. Ankit Mahadevia and Dr. Milind Deshpande, both of whom have deep pedigrees in life sciences venture capital and drug discovery. The current leadership team is headed by Esther Rajavelu, who serves as President, CEO, and CFO, bringing over two decades of experience from roles at Fulcrum Therapeutics and as a senior equities analyst at UBS and Deutsche Bank. She is supported by Chief Operating Officer Timothy Keutzer, a veteran of Cubist Pharmaceuticals with extensive experience in antibiotic development. The company’s Board of Directors is chaired by Frank Thomas, and its strategic direction is backed by notable institutional investors and partners, including GSK, Pfizer Inc., Atlas Venture, and SR One.